TRAMADOL, (+)-

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H25NO2
Molecular Weight	263.3752
Optical Activity	( + )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=CC(=C1)[C@@]2(O)CCCC[C@@H]2CN(C)C

InChI

InChIKey=TVYLLZQTGLZFBW-ZBFHGGJFSA-N

InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C16H25NO2
Molecular Weight	263.3752
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020281s036s038lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.drugs.com/tramadol.html | https://www.drugbank.ca/drugs/DB00193 | http://reference.medscape.com/drug/ultram-er-tramadol-343324 |

Tramadol (sold under the brand name Ultram) is a narcotic analgesic proposed for moderate to severe pain. Tramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. The analgesic properties of Tramadol can be attributed to norepinephrine and serotonin reuptake blockade in the CNS, which inhibits pain transmission in the spinal cord. The (+) enantiomer has the higher affinity for the OP3 receptor and preferentially inhibits serotonin uptake and enhances serotonin release. The (-) enantiomer preferentially inhibits norepinephrine reuptake by stimulating alpha(2)-adrenergic receptors. Tramadol is used primarily to treat mild-severe pain, both acute and chronic. Its analgesic effects take about one hour to come into effect and 2 h to 4 h to peak after oral administration with an immediate-release formulation. On a dose-by-dose basis, tramadol has about one-tenth the potency of morphine and is approximately equally potent when compared to pethidine and codeine. The most common adverse effects of tramadol include nausea, dizziness, dry mouth, indigestion, abdominal pain, vertigo, vomiting, constipation, drowsiness, and headache. Compared to other opioids, respiratory depression and constipation are considered less of a problem with tramadol.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Mu opioid receptor 221 Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24900459	Agonist 2637	1300.0 nM [EC50]
Kappa opioid receptor 108 Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19027293	Agonist 2637	14.0 nM [Ki]
Delta opioid receptor 78 Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19027293	Agonist 2637	9.4 nM [Ki]
Serotonin transporter 172 Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18242987	Inhibitor 8146	1493.0 nM [IC50]
Norepinephrine transporter 183 Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18242987	Inhibitor 8146	3861.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Mild-severe pain 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020281s036s038lbl.pdf	Primary	Approved 8307	ULTRAM Approved Use Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time. Launch Date 7.9418878E11
Osteoarthritis 155 Sources: https://clinicaltrials.gov/ct2/show/NCT01063842	Primary	Phase IV 63	ULTRAM Approved Use Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time. Launch Date 7.9418878E11
Low back pain 22 Sources: https://clinicaltrials.gov/ct2/show/NCT01843660	Primary	Phase IV 63	ULTRAM Approved Use Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time. Launch Date 7.9418878E11

C_max

Value	Dose	Co-administered	Analyte	Population
332 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TRAMADOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
70 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		O-DESMETHYLTRAMADOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
5678 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TRAMADOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
1319 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		O-DESMETHYLTRAMADOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
80% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TRAMADOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

Doses

Dose	Population	Adverse events
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/	healthy, 28 n = 8 Health Status: healthy Age Group: 28 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/	Other AEs: Nausea, Vomiting... Other AEs: Nausea (75%) Vomiting (50%) Headache (25%) Dizziness postural (25%) Vertigo (25%) Dizziness (12.5%) Pruritus (37.5%) Decreased appetite (25%) Hot flush (12.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/
1500 mg single, oral (median) Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/	unknown, 41 n = 359 Health Status: unknown Age Group: 41 Sex: M+F Population Size: 359 Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/	Other AEs: Seizure, Nausea and vomiting... Other AEs: Seizure (14.5%) Nausea and vomiting (53.5%) Tachycardia (4.8%) Hypertension (mild, 38.4%) Arrhythmia (5.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/
300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	Other AEs: Dry mouth, Sweating... Other AEs: Dry mouth (13.1%) Sweating (6.7%) Asthenia (8.6%) Pruritus (7.3%) Arthralgia (5%) Headache (19%) Nausea (25.1%) Somnolence (16.1%) Dizziness (13.6%) Constipation (21.3%) Vomiting (9.3%) Anorexia (5.7%) Insomnia (5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670		substrate 1168	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2B6 648 P-gp 1491

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 1491	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/23331900/	unlikely
CYP2B6 648	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf#page=9 Page: 9.0	yes
CYP2D6 1168	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf#page=5 Page: 5.0	yes	likely (co-administration study) Comment: Coadministration of quinidine, a selective inhibitor of CYP2D6, with tramadol ER resulted in a 50 60% increase in tramadol exposure; pharmacogenomic studies were also conducted: rapid conversion to active metabolite results in higher than expected serum M1 levels. Individuals who are ultra-rapid metabolizers should not use drug. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf#page=5 Page: 5.0
CYP3A4 1670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf#page=5 Page: 5.0	yes	likely (co-administration study) Comment: The concomitant use of ULTRAM with cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine, and phenytoin, may result in an increase in tramadol plasma concentrations; Concomitant administration of tramadol immediate-release tablets with cimetidine, a weak CPY3A4 inhibitor, does not result in clinically significant changes in tramadol pharmacokinetics; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf#page=5 Page: 5.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://accp1.onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.473#page=9 Page: 9.0

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-032272	http://www.3bsc.com/index/pro_info.php?id=53536
AHH Chemical co.,ltd	MT-22547	http://www.ahhchemical.com/product/MT-22547.html
Achemo Scientific Limited	AC-14871	http://www.achemo.com/product_view.asp?ID=4761
Acorn PharmaTech	ACN-038323	http://www.acornpharmatech.com/
Aurora Fine Chemicals LLC	A17.944.638	http://online.aurorafinechemicals.com/info?ID=A17.944.638
Avantor Inc	100568-126	https://us.vwr.com/store/catalog/product.jsp?catalog_number=100568-126
Capot Chemical	20420	http://www.capotchem.com/en/20420.htm
Capot Chemical	PubChem20420	http://www.capotchem.com/en/20420.htm
ChemMol	99056526	http://www.chemmol.com/chemmol/99056526.html
Chiralblock Biosciences	CB10321	http://www.chiralblock.com/products/27203-92-5.html
Finetech	FT-0675346	http://www.finetechnology-ind.com/product/All%20product%20List/123154-38-1.html
Finetech	FT-0604438	http://www.finetechnology-ind.com/product/All%20product%20List/181289-58-7.html
MuseChem	R001869	https://www.musechem.com/product/R001869.html
OChem	30414	http://www.ocheminc.com/index.php?act=psearch&pid=914T774
Sigma-Aldrich	PH003072_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/ph003072
Smolecule	S589647	https://www.smolecule.com/products/s589647
Yuhao Chemical	RT7364	http://www.chemyuhao.com/123154-38-1.html
mcule	MCULE-8198453745	https://mcule.com/MCULE-8198453745/

PubMed

Title	Date	PubMed
Interactions between systemic analgesics.	2001	11799572
Control of non-malignant chronic pain conditions in Japan and the possible future role of tramadol.	2001	11798225
Single-dose dipyrone for acute postoperative pain.	2001	11687057
Analgesic efficacy of tramadol 2 mg kg(-1) for paediatric day-case adenoidectomy.	2001 Apr	11573636
A nonsurgical approach to low back pain.	2001 Apr	11392208
[Control of postoperative pain in heart surgery. Comparison of analgesics].	2001 Apr	11376505
[Factors affecting postoperative pain].	2001 Apr	11333806
Tramadol for postoperative shivering: a double-blind comparison with pethidine.	2001 Apr	11314834
[Sensory neuropathy in HIV infection: pathogenesis and therapy].	2001 Apr 14	11332255
Pharmacology of oral combination analgesics: rational therapy for pain.	2001 Aug	11493367
Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes.	2001 Aug	11454734
Nefopam reduces thermal hypersensitivity in acute and postoperative pain models in the rat.	2001 Dec	11735363
Analgesic efficacy of tramadol if coadministered with ondansetron.	2001 Dec	11726465
Plasma glucose-lowering effect of tramadol in streptozotocin-induced diabetic rats.	2001 Dec	11723065
Pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in human subjects.	2001 Jan	11730570
Comparison of caudal morphine and tramadol for postoperative pain control in children undergoing inguinal herniorrhaphy.	2001 Jul	11442865
Caudal bupivacaine-tramadol combination for postoperative analgesia in pediatric herniorrhaphy.	2001 Jul	11421842
[Analysis of prehospital analgesia administered to victims with traumatic injuries].	2001 Jul-Aug	11586642
[Chronic pain in geriatrics].	2001 Jun	11488082
Anesthetic considerations in a patient with visceral leishmaniasis.	2001 Jun	11444445
Tramadol dependence with no history of substance abuse.	2001 Jun	11384913
Mania and tramadol-fluoxetine combination.	2001 Jun	11384912
Direct tramadol application on sciatic nerve inhibits spinal somatosensory evoked potentials in rats.	2001 Jun	11375844
Tramadol, an alternative to morphine for treating posttraumatic pain in the prehospital situation.	2001 Jun	11375843
Pharmacologic treatment of neuropathic pain.	2001 Mar	11379277
Treatment of refractory major depression with tramadol monotherapy.	2001 Mar	11305709
Abuse of combinations of carisoprodol and tramadol.	2001 May	11372804
The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron.	2001 May	11323369
Effects of tramadol on T lymphocyte proliferation and natural killer cell activity in rats with sciatic constriction injury.	2001 May	11323127
A comparison of tramadol, amitriptyline, and meperidine for postepidural anesthetic shivering in parturients.	2001 Nov	11682416
Gas chromatographic method using nitrogen-phosphorus detection for the measurement of tramadol and its O-desmethyl metabolite in plasma and brain tissue of mice and rats.	2001 Nov 5	11710575
Acetaminophen, aspirin, or Ibuprofen in combination analgesic products.	2001 Nov-Dec	11704782
Urinary disorders on tramadol.	2001 Oct	11824434
Distribution of enantiomers of trans-tramadol and trans-O-demethyltramadol in central nervous system of rats.	2001 Oct	11749767
Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes expressing cloned M1 receptors.	2001 Oct	11561087
Multidimensional on-line solid-phase extraction (SPE) using restricted access materials (RAM) in combination with molecular imprinted polymers (MIP).	2001 Sep	11605750
Intravenous regional anaesthesia using lignocaine and tramadol.	2001 Sep	11603137
Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial.	2001 Sep	11589258
Effects of chronic tramadol on pre- and post-synaptic measures of monoamine function.	2001 Sep	11565620
[Non-opioid analgesics in cancer pain].	2001 Sep	11554055
Psychosomatic reactions to a stressful environment and an attempt at pharmacological modification.	2001 Sep-Oct	11535941
Tramadol and acetaminophen tablets for dental pain.	2001 Summer	11724223
New, non-NSAID alternative.	2002 Feb	11858591
The addition of tramadol to lidocaine does not reduce tourniquet and postoperative pain during iv regional anesthesia.	2002 Feb	11823394
Pharmacological treatment of postoperative shivering: a quantitative systematic review of randomized controlled trials.	2002 Feb	11812718
The role of tricyclic antidepressants and tramadol in palliative care.	2002 Feb	11807215
Stereoselectivity in renal clearance of trans-tramadol and its active metabolite, trans-O-demethyltramadol.	2002 Jan	11860743
Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation.	2002 Jan	11808821
Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care.	2002 Jan	11777190
Meeting the therapeutic challenge of the patient with osteoarthritis.	2002 Jan-Feb	11833521

Patents

Sample Use Guides

In Vivo Use Guide

Chronic: 25 mg PO every morning initially; increased by 25-50 mg/day every 3 days up to 50-100 mg PO q4-6hr PRN; not to exceed 400 mg/day Acute: 50-100 mg PO q4-6hr PRN; not to exceed 400 mg/day

Route of Administration: Oral

In Vitro Use Guide

A malignancy of A549 and PC-9 cells was detected after treatment of 2 μM tramadol for different time (0, 7, 14, or 28 d). The effect of tramadol on the invasion of A549 and PC-9 cells was performed using transwell chambers (6.5 mm diameter and 8 μm pore size; Millipore, Billerica, MA, USA). After treated with 2 μM tramadol for various time, cells were plated onto the Matrigel-coated upper part of the transwell chamber, fetal bovine serum (FBS) medium (20%) was added to the lower wells as a chemoattractant. 48 hours later, non-invading cells were removed, the invaded cells were fixed with 4% paraformaldehyde for 30 min and stained with 1% crystal violet for 30 min. The number of stained cells on the undersurface of the polycarbonate membranes was then counted visually in five random image fields at 200 × magnifications using a microscope (Olympus, Lake Success, NY, USA).

Substance Class	Chemical Created by `admin` on `Sun Dec 18 04:38:14 UTC 2022` Edited by `admin` on `Sun Dec 18 04:38:14 UTC 2022`
Record UNII	0NG5TTM63P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TRAMADOL, (+)-

Common Name

English

(+)-(R,R)-TRAMADOL

Common Name

English

(1R,2R)-2-((DIMETHYLAMINO)METHYL)-1-(3-METHOXYPHENYL)CYCLOHEXANOL

Common Name

English

(+)-TRAMADOL

Common Name

English

Code System Code Type Description

PUBCHEM

33741

Created by admin on Sun Dec 18 04:38:15 UTC 2022 , Edited by admin on Sun Dec 18 04:38:15 UTC 2022

PRIMARY

CHEBI

75725

Created by admin on Sun Dec 18 04:38:15 UTC 2022 , Edited by admin on Sun Dec 18 04:38:15 UTC 2022

PRIMARY

CAS

123154-38-1

Created by admin on Sun Dec 18 04:38:15 UTC 2022 , Edited by admin on Sun Dec 18 04:38:15 UTC 2022

PRIMARY

FDA UNII

0NG5TTM63P

Created by admin on Sun Dec 18 04:38:15 UTC 2022 , Edited by admin on Sun Dec 18 04:38:15 UTC 2022

PRIMARY

Related Record Type Details


					1PE72K8X46

MU-TYPE OPIOID RECEPTOR

TARGET -> AGONIST


					CJZ26L1EGI

SODIUM-DEPENDENT SEROTONIN TRANSPORTER

TARGET -> INHIBITOR


					26J30IC20Q

TRAMADOL, (-)-

ENANTIOMER -> ENANTIOMER

Amount:


					39J1LGJ30J

TRAMADOL

RACEMATE -> ENANTIOMER

Comments:

Agonist of the ?. opioid receptor and inhibits serotonin reuptake.

Amount:

AE	Significance	Dose	Population
Dizziness	12.5%	600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/	healthy, 28 n = 8 Health Status: healthy Age Group: 28 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/
Hot flush	12.5%	600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/	healthy, 28 n = 8 Health Status: healthy Age Group: 28 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/
Decreased appetite	25%	600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/	healthy, 28 n = 8 Health Status: healthy Age Group: 28 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/
Dizziness postural	25%	600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/	healthy, 28 n = 8 Health Status: healthy Age Group: 28 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/
Headache	25%	600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/	healthy, 28 n = 8 Health Status: healthy Age Group: 28 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/
Vertigo	25%	600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/	healthy, 28 n = 8 Health Status: healthy Age Group: 28 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/
Pruritus	37.5%	600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/	healthy, 28 n = 8 Health Status: healthy Age Group: 28 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/
Vomiting	50%	600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/	healthy, 28 n = 8 Health Status: healthy Age Group: 28 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/
Nausea	75%	600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/	healthy, 28 n = 8 Health Status: healthy Age Group: 28 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28881493/
Seizure	14.5%	1500 mg single, oral (median) Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/	unknown, 41 n = 359 Health Status: unknown Age Group: 41 Sex: M+F Population Size: 359 Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/
Tachycardia	4.8%	1500 mg single, oral (median) Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/	unknown, 41 n = 359 Health Status: unknown Age Group: 41 Sex: M+F Population Size: 359 Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/
Arrhythmia	5.3%	1500 mg single, oral (median) Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/	unknown, 41 n = 359 Health Status: unknown Age Group: 41 Sex: M+F Population Size: 359 Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/
Nausea and vomiting	53.5%	1500 mg single, oral (median) Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/	unknown, 41 n = 359 Health Status: unknown Age Group: 41 Sex: M+F Population Size: 359 Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/
Hypertension	mild, 38.4%	1500 mg single, oral (median) Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/	unknown, 41 n = 359 Health Status: unknown Age Group: 41 Sex: M+F Population Size: 359 Sources: https://pubmed.ncbi.nlm.nih.gov/31208192/
Dry mouth	13.1%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
Dizziness	13.6%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
Somnolence	16.1%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
Headache	19%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
Constipation	21.3%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
Nausea	25.1%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
Arthralgia	5%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
Insomnia	5%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
Anorexia	5.7%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
Sweating	6.7%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
Pruritus	7.3%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
Asthenia	8.6%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf
Vomiting	9.3%	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	unhealthy, adult n = 1054 Health Status: unhealthy Condition: osteoarthritis Age Group: adult Population Size: 1054 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

Funbound

Doses

AEs

Overview

OverviewOther

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

C_max

F_unbound